Category Archives: Stem Cell Therapy

Stem Cell Therapy: Plantar Fasciitis
Understand whether the source of your pain might be Plantar Fasciitis, and how biologic regenerative treatments can repair this critical connecting tissue in your foot. For more information,...

By: StemCell ARTS

Go here to see the original:
Stem Cell Therapy: Plantar Fasciitis - Video

Stem Cell Research & Therapy is the major forum for translational research into stem cell therapies. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into stem cell therapeutics and regenerative therapies, including animal models and clinical trials. The journal also provides reviews, viewpoints, commentaries and reports.

There has been an error retrieving the data. Please try again.

Paranasal sinus source of MPCs

Mesenchymal progenitor cells (MPCs) from the ethmoid sinus mucosa have multilineage differentiation potential, high proliferative ability, and an increased capacity for secretion of immunomodulatory cytokines.

Matrix remodeling effects therapeutic potential

There are significant changes in the properties of the extracellular matrix following remodeling after myocardial infarction; characterization of the matrix could increase the efficiency and efficacy of cell therapy treatment.

MHC-mismatched MSCs are immunogenic

All potential donor mesenchymal stromal cells (MSCs) should be immunophenotyped and screened for major histocompatibility complex (MHC) class II expression to prevent inciting an immune reaction.

PSC-derived cardiomyocyte production

Steve Oh and colleagues review progress in the development of platforms for the large scale differentiation of cardiomyocytes from human pluripotent stem cells (PSCs) as part of the cardiovascular regeneration series.

See more here:
Stem Cell Research & Therapy

PUBLIC RELEASE DATE:

29-Jan-2014

Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles

Scientists from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research were today awarded grants totaling more than $3.5 million by California's stem cell agency for their ongoing efforts to advance revolutionary stem cell science in medicine.

Recipients of the awards from the California Institute of Renerative Medicine (CIRM) included Lili Yang ($614,400), who researches how stem cells become rare immune cells; Denis Evseenko ($1,146,468), who is studying the biological niche in which stem cells grow into cartilage; Thomas Otis and Bennet Novitch ($1,148,758), who are using new techniques to study communication between nerve and muscle cells in spinal muscular atrophy; and Samantha Butler ($598,367), who is investigating the molecular elements that drive stem cells to become the neurons in charge of our sense of touch.

"These basic biology grants form the foundation of the revolutionary advances we are seeing in stem cell science," said Dr. Owen Witte, professor and director of the Broad Stem Cell Research Center. "Every cellular therapy that reaches patients must begin in the laboratory with ideas and experiments that will lead us to revolutionize medicine and ultimately improve human life. That makes these awards invaluable to our research effort."

The awards are part of CIRM's Basic Biology V grant program, which fosters cutting-edge research on significant unresolved issues in human stem cell biology, with a focus on unravelling the key mechanisms that determine how stem cells decide which cells they will become. By learning how such mechanisms work, scientists can develop therapies that drive stem cells to regenerate or replace damaged or diseased tissue.

Lili Yang: Tracking special immune cells

The various cells that make up human blood all arise from hematopoietic stem cells. These include special white blood cells called T cells, the "foot soldiers" of the immune system that attack bacteria, viruses and other disease-causing invaders. Among these T cells is a smaller group, a kind of "special forces" unit known as invariant natural killer T cells, or iNKT cells, which have a remarkable capacity to mount immediate and powerful responses to disease when activated and are believed to be important to the immune system's regulation of infections, allergies, cancer and autoimmune diseases such as Type I diabetes and multiple sclerosis.

The iNKT cells develop in small numbers in the blood generally accounting for less than 1 percent of blood cells but can differ greatly in numbers among individuals. Very little is known about how blood stem cells produce iNKT cells.

See the rest here:
Stem cell agency's grants to UCLA help set stage for revolutionary medicine

Stem Cell Therapy - A New Way to Eternal Life?

By: Klentze

View post:
Stem Cell Therapy - A New Way to Eternal Life? - Video

Stem Cell Therapy-Facet Syndrome Back Pain: Alternatives To Back Surgery
How to know if the cause of your back pain or neck pain is Facet Syndrome. Discover how biologic regenerative treatments are able to pick up where traditiona...

By: StemCell ARTS

Read the original:
Stem Cell Therapy-Facet Syndrome Back Pain: Alternatives To Back Surgery - Video

Failure to legislate will hurt research

Tuesday, January 28, 2014

Even though stem cell manufacture has just been licensed in this country, the Governments ongoing failure to legislate in this area means pharmaceutical giants will still be wary of investing here, according to an expert in stem cell therapy.

CCMI General Manager Andrew Finnerty, CCMI Director Tim O'Brien, Minister Sean Sherlock and President of NUI Galway Dr. James Browne. Photograph by Aengus McMahon

Once the stem cells are harvested from the bone marrow of adult donors, they are grown in the Galway laboratory to generate sufficient quantities.

The first clinical trial using these stem cells is being funded by the Health Research Board and Science Foundation Ireland and will investigate the safety of using mesenchymal stem cells (MSCs) isolated from bone marrow for the treatment of critical limb ischemia, a complication associated with diabetes which can lead to limb amputation.

John ODea of the Irish Medical Devices Association (IMDA) said the centre was a key step.

I look forward to seeing its continued growth to assist in developing the skill sets and techniques that will be needed to embrace the new manufacturing opportunities that this exciting area will bring, he said.

The centre, one of a handful in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

However, Dr Stephen Sullivan, chief scientific officer with the Irish Stem Cell Foundation warned all stem cell research operates at a pan-global level driven by big pharma and international equity firms and these players will only engage with researchers in countries where there is solid stem cell legislation in place. He welcomed the centre as a first step but said if Ireland is to compete at a top international standard, legislation remains necessary.

Read more here:
Failure to legislate ‘will hurt research’